Literature DB >> 22584586

A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L.

Kavitha Gnanasambandan1, Andrew T Magis, Peter P Sayeski.   

Abstract

Jak2 mutations in the exon 14 and exon 12 regions that cause constitutive activation have been associated with myeloproliferative neoplasms. We have previously shown that a pi stacking interaction between F617 and F595 is important for the constitutive activation of Jak2-V617F (Gnanasambandan et al., Biochemistry 49:9972-9984, 2010). Here, using a combination of molecular dynamics (MD) simulations and in vitro mutagenesis, we studied the molecular mechanism for the constitutive activation of the Jak2 exon 12 mutation, H538Q/K539L. The activation levels of Jak2-H538Q/K539L were found to be similar to that of Jak2-V617F, and Jak2-H538Q/K539L/V617F. Data from MD simulations indicated a shift in the salt bridge interactions of D620 and E621 with K539 in Jak2-WT to R541 in Jak2-H538Q/K539L. When compared to Jak2-WT, K539A mutation resulted in increased activation, while K539D or K539E mutations diminished Jak2 activation by 50 %. In the context of Jak2-H538Q/K539L, R541A mutation reduced its activation by 50 %, while R541D and R541E mutations returned its activation levels to that of Jak2-WT. Collectively, these results indicate that a shift in the salt bridge interaction of D620 and E621 with K539 in Jak2-WT to R541 in Jak2-H538Q/K539L is critical for constitutive activation of this Jak2 exon 12 mutant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584586     DOI: 10.1007/s11010-012-1326-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  28 in total

Review 1.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

2.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Authors:  P Peeters; S D Raynaud; J Cools; I Wlodarska; J Grosgeorge; P Philip; F Monpoux; L Van Rompaey; M Baens; H Van den Berghe; P Marynen
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

3.  Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Authors:  Francesco Passamonti; Chiara Elena; Susanne Schnittger; Radek C Skoda; Anthony R Green; François Girodon; Jean-Jacques Kiladjian; Mary Frances McMullin; Marco Ruggeri; Carles Besses; Alessandro M Vannucchi; Eric Lippert; Heinz Gisslinger; Elisa Rumi; Thomas Lehmann; Christina A Ortmann; Daniela Pietra; Cristiana Pascutto; Torsten Haferlach; Mario Cazzola
Journal:  Blood       Date:  2011-01-11       Impact factor: 22.113

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

Review 5.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Hydrophilicity of cavities in proteins.

Authors:  L Zhang; J Hermans
Journal:  Proteins       Date:  1996-04

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses.

Authors:  Claude Haan; Daniela C Kroy; Stefan Wüller; Ulrike Sommer; Tanja Nöcker; Catherine Rolvering; Iris Behrmann; Peter C Heinrich; Serge Haan
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

10.  Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.

Authors:  Tai-Sung Lee; Wanlong Ma; Xi Zhang; Hagop Kantarjian; Maher Albitar
Journal:  BMC Struct Biol       Date:  2009-09-10
View more
  1 in total

1.  STAT1 activation in association with JAK2 exon 12 mutations.

Authors:  Anna L Godfrey; Edwin Chen; Charles E Massie; Yvonne Silber; Francesca Pagano; Beatriz Bellosillo; Paola Guglielmelli; Claire N Harrison; John T Reilly; Frank Stegelmann; Fontanet Bijou; Eric Lippert; Jean-Michel Boiron; Konstanze Döhner; Alessandro M Vannucchi; Carlos Besses; Anthony R Green
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.